40th week of 2015 patent applcation highlights part 29 |
Patent application number | Title | Published |
20150274786 | Pesticidal Toxin Proteins Active Against Coleopteran Insects - The invention generally relates to the field of insect inhibitory toxin proteins. A novel class of proteins exhibiting insect inhibitory activity against agriculturally relevant pests of crop plants and seeds are disclosed. Insecticidal activity is particularly effective against the | 2015-10-01 |
20150274787 | METHOD FOR RECOMBINANT PRODUCTION OF LABYRINTHOPEPTINS AND FUNCTIONAL DERIVATIVES THEREOF - The present invention relates to a method for recombinant production of Labyrinthopeptins and functional derivatives thereof. Moreover, the present invention relates to novel functional derivatives of Labyrinthopeptins. | 2015-10-01 |
20150274788 | LANTIBIOTIC DERIVATIVES AND PROCESS FOR THEIR PREPARATION - The present invention concerns novel antibiotic compounds, which are lantibiotics, the processes for their preparation, their pharmaceutically acceptable salts, pharmaceutical compositions containing the lantibiotics, and their use as antibacterial agents. Compounds designated as lantibiotics, such as those of the present invention, are peptides belonging to the general class of antibiotic compounds, and are further generally characterized by the presence of the amino acids lanthionine and/or 3-methyllanthionine. The novel lantibiotic compounds are active against bacterial infections caused by | 2015-10-01 |
20150274789 | COMPOUNDS AND METHODS FOR THE PRODUCTION OF SUCKERIN AND USES THEREOF - Sucker ring tooth (SRT) proteins called Suckerins were identified from the sucker tissue of three distantly related Decapodiformes species. These proteins assemble into silk-like beta-sheet reinforced materials. The use of suckerin proteins to produce fibres, films and tissue scaffolds is also described. | 2015-10-01 |
20150274790 | MODULAR ANTIGEN TRANSPORTATION MOLECULES AND USES THEROF - The present invention relates to (isolated) recombinant proteins, also referred to as improved MAT (iMAT) molecules, comprising at least one translocation module, at least one targeting module and at least one antigen module, wherein at least one cysteine residue is substituted with a different amino acid residue. Such iMAT molecules are useful specifically as vaccines, e.g., for therapy and/or prevention of allergies and/or infectious diseases and/or prevention of transmission of infectious diseases in equines. The present invention further relates to nucleic acids encoding such iMAT molecules, corresponding vectors and primary cells or cell lines. | 2015-10-01 |
20150274791 | USE OF NATURAL ANTIOXIDANTS DURING ENZYMATIC HYDROLYSIS OF AQUATIC PROTEIN TO OBTAIN HIGH QUALITY AQUATIC PROTEIN HYDROLYSATES - The present invention relates to the use of natural antioxidants from marine algae extracts, such as seaweed extracts and preferably | 2015-10-01 |
20150274792 | Novel Method for Treating Spinal Cord Injury Using HMGB1 Fragment - Fragment peptides having a proper length, which consists of a portion of the HMGB1 protein were synthesized, and the peptides were confirmed to show therapeutic effects on injury of the spinal cord. | 2015-10-01 |
20150274793 | VEGF Analogs and Methods of Use - Modified VEGF proteins that inhibit VEGF-mediated activation or proliferation of endothelial cells are disclosed. The analogs may be used to inhibit VEGF-mediated activation of endothelial cells in angiogenesis-associated diseases such as cancer, inflammatory diseases, eye diseases, and skin disorders. | 2015-10-01 |
20150274794 | CHAPERONIN 10 VARIANTS - The invention relates generally to chaperonin 10 N-terminal variants. More specifically, the invention relates to chaperonin 10 N-terminal variants with enhanced immunomodulatory capacity and/or enhanced binding affinity for pathogen-associated molecular patterns (PAMPs) and/or damage-associated molecular patterns (PAMPs). | 2015-10-01 |
20150274795 | METHODS FOR PROTECTING DOPAMINERGIC NEURONS FROM STRESS AND PROMOTING PROLIFERATION AND DIFFERENTIATION OF OLIGODENDROCYTE PROGENITORS BY NRG-2 - The invention features methods of treatment and diagnosis using NRG-2 polypeptides, nucleic acid molecules, and antibodies. The invention also provides novel NRG-2 polypeptides and nucleic acid molecules. | 2015-10-01 |
20150274796 | MEANS AND METHODS FOR MODULATING NOTCH3 PROTEIN EXPRESSION AND/OR THE CODING REGION OF NOTCH3; COMPOSITIONS AND USE THEREOF IN THE TREATMENT OF CADASIL - The invention among other provides means and methods for modulating NOTCH3 expression and/or protein coding domain. In one aspect the invention provides a method for at least reducing an elevated level of NOTCH3 protein in a NOTCH3 expressing cell or the immediate vicinity thereof said method comprising providing said cell with an anti-sense oligonucleotide specific for NOTCH3 mRNA or pre-mRNA thereby decreasing production of said NOTCH3 protein or thereby altering the protein coding region in said NOTCH3 mRNA or pre-mRNA | 2015-10-01 |
20150274797 | Antibody Fusion Proteins with a Modified FcRn Binding Site - Disclosed are antibody fusion proteins with a modified FcRn binding site and nucleic acid molecules encoding them. The antibody fusion protein include two polypeptide chains, wherein the first polypeptide chain includes a biologically active molecule linked to at least a portion of an immunoglobulin constant region. The second polypeptide chain includes at least a portion of an immunoglobulin constant region. One of the polypeptide chains includes a mutation in the FcRn binding site that reduces binding to FcRn. Also disclosed are methods of producing the fusion proteins and methods of using the fusion proteins for treating diseases and conditions alleviated by the administration of the fusion proteins. | 2015-10-01 |
20150274798 | NOVEL GH-RH ANALOGS WITH POTENT AGONISTIC EFFECTS - There are provided a novel series of peptide analogs of hGH-RH(1-29)NH | 2015-10-01 |
20150274799 | GLP-1 ANALOGUE, ITS PREPARATION METHODS AND USE THEREOF - Provided is a GLP-1 analogue having the structure as shown in the general formula A: | 2015-10-01 |
20150274800 | GLUCOSE-REGULATING POLYPEPTIDES AND METHODS OF MAKING AND USING SAME - The present invention relates to compositions comprising glucose regulating peptides linked to extended recombinant polypeptide (XTEN), isolated nucleic acids encoding the compositions and vectors and host cells containing the same, and methods of making and using such compositions in treatment of glucose regulating peptide-related diseases, disorders, and conditions. | 2015-10-01 |
20150274801 | ACYLATED GLUCAGON ANALOGUES - The present invention relates to novel peptide compounds which have an improved physical stability in solution and improved solubility at neutral pH, to the use of the compounds in therapy, to methods of treatment comprising administration of the compounds to patients in need thereof, and to the use of the compounds in the manufacture of medicaments. The compounds of the invention are of particular interest in relation to the treatment of hyperglycemia, diabetes and obesity, as well as a variety of diseases or conditions associated with hyperglycemia, diabetes and obesity. | 2015-10-01 |
20150274802 | INSULIN ANALOG DIMERS - Disclosed herein are insulin analog dimers having unique insulin receptor agonist activity based on insulin polypeptide sequences, the site of dimerization and the length of the dimerization linker that connects the two insulin polypeptides. In accordance with one embodiment the first and second insulin polypeptide are independently a two chain insulin analog or a single chain analog and the first and second insulin polypeptides are linked to one another via a B29-B29′, B1-C8, B1-B1 or C8-C8 linkage. | 2015-10-01 |
20150274803 | LONG-ACTING SINGLE-CHAIN INSULIN ANALOGUES - A single-chain insulin analogue containing a basic side chain at position A8 (Arginine, Histidine, Lysine, or Ornithine), a basic side chain at position B29 (Arginine, Histidine, Lysine, or Ornithine), and a foreshortened C-domain of length 6-11 residues is provided. Residues C1 and C2 of the C-domain have a net negative charge of −1 or −2; C3 is chosen from a group consisting of Gly, Ala, Pro, or Ser; and the remaining C-domain segment is successively derived from the C-domain of IGF-II (RRSR, SRRSR, VSRRSR, RVSRRSR, or SRVSRRSR; SEQ ID NO: 13). A method of treating a patient with diabetes mellitus or obesity comprises administering a physiologically effective amount of the insulin analogue or a physiologically acceptable salt thereof to a patient. | 2015-10-01 |
20150274804 | FC GAMMA RECEPTOR IIB VARIANTS - The present invention relates to a nucleic acid sequence which encodes a protein of SEQ ID NO: 1; a vector comprising said nucleic acid sequence and a host cell comprising said nucleic acid sequence or said vector. The present invention also relates to a protein obtained or obtainable by expression of said nucleic acid sequence or said vector in a host cell. Furthermore, the present invention relates to a protein encoded by a nucleic acid sequence of SEQ ID NO: 6. Additionally comprised by the present invention are pharmaceutical compositions and a method of manufacturing the same. | 2015-10-01 |
20150274805 | Elastic Hydrogel - The present invention relates to hydrogels and to the use of hydrogels for repair or restoration of tissue. In particular, the hydrogels of the present invention can be used for the repair or restoration of cardiac tissue. | 2015-10-01 |
20150274806 | FIBRONECTIN BASED SCAFFOLD DOMAIN PROTEINS THAT BIND IL-23 - The present invention relates to fibronectin based scaffold domain protein that bind interleukin 23 (IL-23), specifically the p19 subunit of IL-23. The invention also relates to the use of the innovative proteins in therapeutic applications to treat autoimmune diseases. The invention further relates to cells comprising such proteins, polynucleotide encoding such proteins or fragments thereof, and to vectors comprising the polynucleotides encoding the innovative proteins. | 2015-10-01 |
20150274807 | METHOD FOR PREPARING HOMODIMER PROTEIN MIXTURE BY USING CHARGE REPULSION EFFECT - The invention relates to a method for preparing a homodimer protein mixture by using repulsive interaction of charges. The method comprises the step of replacing part of residues with the opposite-charged residues, so that different proteins or antibodies are unfavorable to forming heterodimers due to the repulsive interaction between like charges, while same proteins or antibodies are favorable to forming homodimers due to attractive interaction between opposite charges. The homodimer protein mixture obtained according to the method of the invention can simultaneously act on different epitopes of the same target, and simultaneously inhibit the effects of a plurality of antigens by binding to the antigens from different sources, thereby providing a new approach towards immunological diagnosis and treatment of tumors and other diseases. | 2015-10-01 |
20150274808 | Methods of Preventing and Removing Trisulfide Bonds - The present invention pertains to methods of preventing and eliminating trisulfide bonds in proteins such as antibodies. In one embodiment, trisulfide bonds in proteins are converted to disulfide bonds as part of chromatographic purification procedures. In another embodiment, the formation of trisulfide bonds in proteins is inhibited by implementation of methods described herein during the cell culture production of such proteins. In another embodiment, monoclonal antibodies are produced by the methods described herein. | 2015-10-01 |
20150274809 | ANTIBODY CONSTANT REGION VARIANT - By altering amino acid sequences, the present inventors successfully produced constant regions that can confer antibodies with particularly favorable properties for pharmaceutical agents. When used to produce antibodies, the altered constant regions produced according to the present invention significantly reduce heterogeneity. Specifically, the antibody homogeneity can be achieved by using antibody heavy chain and light chain constant regions introduced with alterations provided by the present invention. More specifically, the alterations can prevent the loss of homogeneity of antibody molecules due to disulfide bond differences in the heavy chain. Furthermore, in a preferred embodiment, the present invention can improve antibody pharmacokinetics as well as prevent the loss of homogeneity due to C-terminal deletion in antibody constant region. | 2015-10-01 |
20150274810 | Disulfide Stabilised Antibodies and Fragments Thereof - The present disclosure provides an antibody or antibody fragment comprising at least one Fab molecule, wherein the light chain variable region, V | 2015-10-01 |
20150274811 | HUMAN BINDING MOLECULES ABLE TO NEUTRALIZE INFLUENZA A VIRUSES OF PHYLOGENETIC GROUP 1 AND PHYLOGENETIC GROUP 2 AND INFLUENZA B VIRUSES - Described are binding molecules, such as human monoclonal antibodies, that bind to an epitope in the stem region of hemagglutinin of influenza A viruses of phylogenetic group 1 and group 2, as well as influenza B viruses, and have a broad neutralizing activity against such influenza viruses. Provided are nucleic acid molecules encoding the binding molecules, their sequences, and compositions comprising the binding molecules. The binding molecules can be used, for example, in the diagnosis, prophylaxis, and/or treatment of influenza A viruses of phylogenetic groups 1 and 2, as well as influenza B viruses. | 2015-10-01 |
20150274812 | ANTI-INFLUENZA B VIRUS HEMAGGLUTININ ANTIBODIES AND METHODS OF USE - The present invention provides anti-influenza B virus hemagglutinin antibodies, compositions comprising anti-influenza B virus hemagglutinin antibodies, and methods of using the same. | 2015-10-01 |
20150274813 | Broadly-Neutralizing Anti-HIV Antibodies - The present invention relates to anti-HIV antibodies. Also disclosed are related methods and compositions. HIV causes acquired immunodeficiency syndrome (AIDS), a condition in humans characterized by clinical features including wasting syndromes, central nervous system degeneration and profound immunosuppression that results in life-threatening opportunistic infections and malignancies. Since its discovery in 1981, HIV type 1 (HIV-1) has led to the death of at least 25 million people worldwide. | 2015-10-01 |
20150274814 | METHODS OF TREATING AND PREVENTING STAPHYLOCOCCUS AUREUS INFECTIONS AND ASSOCIATED CONDITIONS - The present invention relates to methods and compositions for preventing and treating | 2015-10-01 |
20150274815 | TREATMENT OF CENTRAL NERVOUS SYSTEM (CNS) INJURY - The invention features compositions for use in increasing neuron or neurite growth, including for the treatment of Central Nervous System (CNS) injury, such as human arylsulfatase B. | 2015-10-01 |
20150274816 | NOVEL HUMAN GENES RELATING TO RESPIRATORY DISEASES AND OBESITY - This invention relates to isolated nucleic acids comprising genes of human chromosome 12q23-qter and the proteins encoded by these genes. Expression vectors and host cells containing such genes or fragments thereof, as well as antibodies to the proteins encoded by these nucleic acids are also included herein. | 2015-10-01 |
20150274817 | METHOD FOR INHIBITING BONE RESORPTION - The invention is directed to a method of inhibiting bone resorption. The method comprises administering to a human an amount of sclerostin inhibitor that reduces a bone resorption marker level for at least 2 weeks. The invention also provides a method of monitoring anti-sclerostin therapy comprising measuring one or more bone resorption marker levels, administering a sclerostin binding agent, then measuring the bone resorption marker levels. Also provided is a method of increasing bone mineral density; a method of ameliorating the effects of an osteoclast-related disorder; a method of treating a bone-related disorder by maintaining bone density; and a method of treating a bone-related disorder in a human suffering from or at risk of hypocalcemia or hypercalcemia, a human in which treatment with a parathyroid hormone or analog thereof is contraindicated, or a human in which treatment with a bisphosphonate is contraindicated. | 2015-10-01 |
20150274818 | COMPOUNDS AND METHODS FOR TREATING PAIN - This disclosure provides compositions and methods for controlling pain. In particular the disclosure provides a method for controlling pain comprising co-administration of an NGF antagonist and a TNFα antagonist. The NGF antagonist and the TNFα antagonist can be separate molecules or part of a multifunctional polypeptide, e.g., a multispecific binding molecule that comprises an NGF antagonist domain and a TNFα antagonist domain. This disclosure also provides multifunctional polypeptides, e.g., multispecific binding molecules, comprising an NGF antagonist domain, and a TNFα antagonist domain. The method provides improved pain control. Administration of an NGF antagonist and a TNFα antagonist as provided herein can control pain in the subject more effectively than an equivalent amount of the NGF antagonist or the TNFα antagonist administered alone. | 2015-10-01 |
20150274819 | STABLE AQUEOUS RECOMBINANT PROTEIN FORMULATIONS - The present invention provides a sterile pharmaceutical formulation suitable for parenteral administration comprising: (a) a recombinant protein; (b) sodium acetate; (c) arginine hydrochloride; (d) a cryoprotecant; and (e) a surfactant. | 2015-10-01 |
20150274820 | STABLE AND SOLUBLE ANTIBODIES INHIBITING VEGF - The present invention relates to soluble and stable anti-VEGF imunobinders comprising CDRs from rabbit monoclonal antibodies. Said antibodies are designed for the diagnosis and/or treatment of VEGF-mediated disorders. The hybridomas, nucleic acids, vectors and host cells for expression of the recombinant antibodies of the invention, methods for isolating them and the use of said antibodies in medicine are also disclosed. | 2015-10-01 |
20150274821 | TREATMENT OF INFLAMMATORY PAIN USING IL-20 ANTAGONISTS - Reducing inflammatory pain in a subject having or being suspected of having an inflammatory pain using an IL-20 antagonist, which can be an antibody that blocks a signaling pathway mediated by IL-20. Such antibodies include anti-IL-20 antibodies and anti-IL-20R antibodies that specifically block the IL-20 signaling pathway. | 2015-10-01 |
20150274822 | ANTAGONISTS OF IL-6 TO RAISE ALBUMIN AND/OR LOWER CRP - The present invention is directed to therapeutic methods using IL-6 antagonists such as antibodies and fragments thereof having binding specificity for IL-6 to improve survivability or quality of life of a patient in need thereof. In preferred embodiments, the anti-IL-6 antibodies will be humanized and/or will be aglycosylated. Also, in preferred embodiments these patients will comprise those exhibiting (or at risk of developing) an elevated serum C-reactive protein level or a reduced serum albumin level prior to treatment. In another preferred embodiment, the patient's Glasgow Prognostic Score will be increased and survivability will preferably be improved. | 2015-10-01 |
20150274823 | ANTIBODIES TO IL-6 AND USE THEREOF - The present invention is directed to antibodies and fragments thereof and humanized versions thereof having binding specificity for IL-6. Another embodiment of this invention relates to the antibodies described herein, and binding fragments thereof, comprising the sequences of the V | 2015-10-01 |
20150274824 | ANTAGONIST ANTIBODY FOR THE TREATMENT OF CANCER - Antibodies, humanized antibodies, resurfaced antibodies, antibody fragments, derivatized antibodies, and conjugates of same with cytotoxic agents, which specifically bind to, and inhibit A class of Eph receptors, antagonize the effects of growth factors on the growth and survival of tumor cells, and which have minimal agonistic activity or are preferrentially devoid of agonist activity. Said antibodies and fragments thereof may be used in the treatment of tumors that express elevated levels of A class of Eph receptors, such as breast cancer, colon cancer, lung cancer, ovarian carcinoma, synovial sarcoma and pancreatic cancer, and said derivatized antibodies may be used in the diagnosis and imaging of tumors that express elevated levels of A class of Eph receptors. Also provided are cytotoxic conjugates comprising a cell binding agent and a cytotoxic agent, therapeutic compositions comprising the conjugate, methods for using the conjugates in the inhibition of cell growth and the treatment of disease, and a kit comprising the cytotoxic conjugate are disclosed are all embodiments of the invention. In particular, the cell binding agent is a monoclonal antibody, and epitope-binding fragments thereof, that recognizes and binds the A class of Eph receptors. | 2015-10-01 |
20150274825 | Antibodies that Bind and Block Triggering Receptor Expressed on Myeloid Cells-1 (TREM-1) - The invention relates to antibodies that are capable of specifically binding TREM-1 and preventing the activation of TREM-1, a protein expressed on monocytes, macrophages and neutrophils. Such antibodies find utility in the treatment of individuals with an inflammatory disease, such as rheumatoid arthritis and inflammatory bowel disease. | 2015-10-01 |
20150274826 | THERAPEUTIC CD47 ANTIBODIES - Provided are monoclonal antibodies and antigen-binding fragments thereof that bind to CD47 of multiple mammalian species, block the binding of SIRPalpha and TSP1 to CD47, promote phagocytosis of susceptible cancer cells, and reverse TSP1 inhibition of nitric oxide signaling, as well as monoclonal antibodies and antigen binding fragments thereof that compete with the former for binding to CD47 and that exhibit similar biological activities. Also provided are combinations of any of the foregoing. Such antibody compounds are variously effective in 1) treating tissue ischemia and ischemia-reperfusion injury (IRI) in the setting of organ preservation and transplantation, pulmonary hypertension, sickle cell disease, myocardial infarction, stroke, and other instances of surgery and/or trauma in which IRI is a component of pathogenesis; 2) in treating autoimmune and inflammatory diseases; and 3) as anti-cancer agents for treating susceptible cancer cells, promoting their phagocytic uptake and clearance. | 2015-10-01 |
20150274827 | Recombinant TNF Ligand Family Member Polypeptides with Antibody Binding Domain and Uses Therefor - The present invention relates in general to the field of TNF ligand family members. In more detail the present invention relates to polypeptides comprising at least three components A, each of which comprises the sequence of a TNF homology domain (THD) of a TNF ligand family member, or a functional derivative thereof, and comprising at least one component B consisting of a V | 2015-10-01 |
20150274828 | HUMAN ANTI-HUMAN EPIDEMIC GROWTH FACTOR RECEPTOR ANTIBODY AND ENCODING GENE AND APPLICATION THEREOF - The present invention provides human anti-human epidermal growth factor receptor (EGFR) antibodies and their encoding genes and applications thereof. By gene engineering means and phage surface display technology, the present invention screens anti-human EGFR gene engineering single chain antibody from fully synthetic single chain human antibody library, and obtains the antibody variable gene sequence thereof, and based thereon, constructs intact human monoclonal antibody, to further obtain high-purity antibody protein. The binding affinity of the antibody of the present invention with human EGFR is no more than 1 nM, and the mutants affinity thereof is no more than 10 nM; and the identification of the immunity activity and bioactivity of antibodies protein IgG is completed, confirming that the antibody of the present invention has good bioactivity of inhibiting the tumor growth of EGFR expressing cell A431 tumor-bearing model mouse. The antibodies of the present invention provides specific antibody drugs for preventing and treating EGFR targeted tumor and other diseases such as inflammation and autoimmune diseases. | 2015-10-01 |
20150274829 | Compositions and Methods Relating to Anti-IGF-1 Receptor Antibodies - The present invention provides compositions and methods relating to or derived from anti-IGF-1R antibodies. In particular embodiments, the invention provides fully human, humanized, or chimeric anti-IGF-1R antibodies that bind human IGF-1R, IGF-1R-binding fragments and derivatives of such antibodies, and IGF-1R-binding polypeptides comprising such fragments. Other embodiments provide nucleic acids encoding such antibodies, antibody fragments and derivatives and polypeptides, cells comprising such polynucleotides, methods of making such antibodies, antibody fragments and derivatives and polypeptides, and methods of using such antibodies, antibody fragments and derivatives and polypeptides, including methods of treating or diagnosing subjects having IGF-1R-related disorders or conditions. | 2015-10-01 |
20150274830 | ANTIBODIES AGAINST HUMAN CSF-1R AND USES THEREOF - The present invention relates to antibodies against human CSF-1R (anti-CSF-1R antibody), methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof. | 2015-10-01 |
20150274831 | ANTIBODIES AGAINST HUMAN CSF-1R AND USES THEREOF - The present invention relates to antibodies against human CSF-1R (anti-CSF-1R antibody), methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof. | 2015-10-01 |
20150274832 | DAC HYP COMPOSITIONS AND METHODS - The present disclosure relates to compositions of daclizumab suitable for subcutaneous administration and methods of manufacturing thereof. | 2015-10-01 |
20150274833 | RECOMBINANT BISPECIFIC ANTIBODY BINDING TO CD20 AND CD95 - A bispecific antibody format, which comprises a) a Fab fragment comprising a first binding site for a first antigen; b) an scFv fragment comprising a second binding site for a second antigen; and c) a CH2 domain, wherein the Fab fragment and the scFv fragment are linked via the CH2 domain, wherein the first antigen is CD95 and the second antigen is CD20; or the first antigen is CD20 and the second antigen is CD95. | 2015-10-01 |
20150274834 | COMBINATION THERAPY OF AN AFUCOSYLATED CD20 ANTIBODY WITH FLUDARABINE AND/OR MITOXANTRONE - The present invention is directed to the combination therapy of an afucosylated anti-CD20 antibody with fludarabine and/or mitoxantrone for the treatment of cancer, especially to the combination therapy of CD20 expressing cancers with an afucosylated humanized B-Ly1 antibody with fludarabine and/or mitoxantrone. | 2015-10-01 |
20150274835 | HUMAN MONOCLONAL ANTI-PD-L1 ANTIBODIES AND METHODS OF USE - The present invention comprises human monoclonal antibodies that bind to PD-L1 (also known as programmed death ligand 1 or B7H1). Binding of the invented antibody to PD-L1 inhibits binding to its receptor, PD1 (programmed death 1), and ligand-mediated activities and can be used to treat cancer and chronic viral infections. | 2015-10-01 |
20150274836 | MESOTHELIN ANTIBODIES AND METHODS FOR ELICITING POTENT ANTITUMOR ACTIVITY - Described herein is the use of phage display antibody engineering technology and synthetic peptide screening to identify SD1 and SD2, human single-domain antibodies to mesothelin. SD1 recognizes a conformational epitope at the C-terminal end (residues 539-588) of human mesothelin close to the cell surface. SD2 binds full-length mesothelin. To investigate SD1 as a potential therapeutic agent, a recombinant human Fc (SD1-hFc) fusion protein was generated. The SD1-hFc protein exhibits strong complement-dependent cytotoxicity (CDC), in addition to antibody-dependent cellular cytotoxicity (ADCC), against mesothelin-expressing tumor cells. Furthermore, the SD1-hFc protein causes significant tumor growth inhibition of tumor xenografts in nude mice. SD1 and SD2 are the first human single-domain antibodies targeting mesothelin-expressing tumors. | 2015-10-01 |
20150274837 | Antibody Glycosylation Variants Having Increased Antibody-Dependent Cellular Cytotoxicity - The present invention relates to the field of glycosylation engineering of proteins. More particularly, the present invention relates to glycosylation engineering to generate proteins with improved therapeutic properties, including antibodies with increased antibody-dependent cellular cytotoxicity. | 2015-10-01 |
20150274838 | Antibodies Reactive with B7-H3, Immunologically Active Fragments Thereof and Uses Thereof - The present invention relates to antibodies and their fragments that are immunoreactive to the mammalian, and more particularly, the human B7-H3 receptor and to uses thereof, particularly in the treatment of cancer and inflammation. The invention thus particularly concerns humanized B7-H3-reactive antibodies and their immunoreactive fragments that are capable of mediating, and more preferably enhancing the activation of the immune system against cancer cells that are associated with a variety of human cancers. | 2015-10-01 |
20150274839 | Antibodies to Non-Functional P2X7 Receptor - The present invention provides antibodies that specifically bind to P2X | 2015-10-01 |
20150274840 | ANTI-ADAM28 ANTIBODY FOR TREATING CANCER - The present invention provides an antibody that specifically binds to human ADAM28, inhibits enzyme activity of human ADAM28, and has an activity to suppress metastasis of a cancer cell that expresses human ADAM28. The antibody of the present invention can be a human antibody. | 2015-10-01 |
20150274841 | COMPOSITIONS AND METHODS FOR TREATMENT OF DIABETIC MACULAR EDEMA - Disclosed herein are compositions comprising one or more antibodies that specifically bind active plasma kallikrein (e.g., human plasma kallikrein) and methods of using such compositions for the treatment of retinal diseases, such as diabetic macular edema. | 2015-10-01 |
20150274842 | ADAM-15 ANTIBODIES AND IMMUNOGENIC PEPTIDES - The present invention relates to antibodies and antigen-binding fragments thereof, immunogenic peptide(s), and siRNA molecules which are capable of inhibiting neovascularization and/or angiogenesis and endothelial cell proliferation. The invention relates to antibodies and antigen-binding fragments thereof with specificity towards the metalloprotease domain of ADAM 15 and to immunogenic peptide(s) that elicits such antibodies. The invention also relates to compositions and kits comprising the antibodies and immunogenic peptide(s) of the invention, as well as methods and uses of the antibodies and antigen-binding fragments thereof and immunogenic peptide(s), as well as siRNA molecules. | 2015-10-01 |
20150274843 | Hyaluronic Acid Decomposition-Promoting Factor and Inhibitor Thereof - The present invention is directed to KIAA1199, which is a novel factor involved in decomposition of hyaluronic acid, and to use thereof. More specifically, the invention is directed to a hyaluronic acid decomposition-promoting agent containing the KIAA1199 gene and a protein encoded by the gene; to a hyaluronic acid decomposition-inhibiting agent characterized by inhibiting the activity or expression thereof (including an siRNA or a monoclonal antibody); and to a method for screening a novel hyaluronic acid decomposition-controlling agent, in which the method contains employing the expression of KIAA1199 as an index. | 2015-10-01 |
20150274844 | HETERODIMER BINDING PROTEINS AND USES THEREOF - The present disclosure provides polypeptide heterodimers formed between two different single chain fusion polypeptides via natural heterodimerization of an immunoglobulin CH1 region and an immunoglobulin light chain constant region (CL). The polypeptide heterodimer comprises two or more binding domains that specifically bind one or more targets (e.g., a receptor). In addition, both chains of the heterodimer further comprise an Fc region portion. The present disclosure also provides nucleic acids, vectors, host cells and methods for making polypeptide heterodimers as well as methods for using such polypeptide heterodimers, such as in directing T cell activation, inhibiting solid malignancy growth, and treating autoimmune or inflammatory conditions. | 2015-10-01 |
20150274845 | BISPECIFIC ANTIBODIES SPECIFIC FOR T-CELL ACTIVATING ANTIGENS AND A TUMOR ANTIGEN AND METHODS OF USE - The present invention relates to bispecific antibodies that specifically bind a T-cell activating antigen and a Tumor Antigen (TA), comprising a first Fab fragment and a second Fab fragment, wherein either the variable regions or the constant regions of the second Fab heavy and light chain are exchanged; and wherein the bispecific antibody does not comprise a Fc domain; methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof. | 2015-10-01 |
20150274846 | ARTIFICIAL ANTIGEN OF AFLATOXIN BIOSYNTHETIC PRECURSOR STERIGMATOCYSTIN AND METHOD FOR PREPARING SAME - An artificial antigen of aflatoxin biosynthetic precursor terigmatocystin (ST) and a method for preparing same. Firstly, hydroxyacetic acid is reacted with the double bound of the difuran ring in the aflatoxin biosynthetic precursor ST, yielding an aflatoxin biosynthetic precursor ST hapten with an active carboxymethoxy group. Secondly, a carboxyl group on the ST hapten is attached to an amino group on a carrier protein. At last, the artificial antigen of aflatoxin biosynthetic precursor ST is obtained by dialysis and lyophilize. | 2015-10-01 |
20150274847 | ANTIBODY TOXIN CONJUGATES - The present invention provides conjugates formed between toxins and sugars and toxins and peptides, such as antibodies. In an exemplary embodiment, a toxin-sugar construct is conjugated to an antibody through an intact glycosyl linking group. | 2015-10-01 |
20150274848 | FLAME RETARDANT MODIFIED CELLULOSIC NANOMATERIALS (FR-CNs) PREPARED USING PHOSPHORUS-CONTAINING MONOMERS - In accordance with some embodiments of the present invention, a composite material is prepared by blending a flame retardant modified cellulosic nanomaterial (FR-CN) filler into a polymer, wherein the FR-CN filler comprises a cellulosic nanomaterial (e.g., cellulose nanocrystals (CNCs) and/or cellulose nanofibrils (CNFs)) having a surface functionalized to incorporate a phosphorus-containing moiety. In some embodiments, the FR-CN filler is prepared by reacting hydroxyl groups on the surface of the cellulosic nanomaterial and a halogenated phosphorous-containing monomer (e.g., diphenyl phosphoryl chloride). In some embodiments, the surface of the cellulosic nanomaterial is further functionalized to incorporate an orthogonal functionality selected to enhance the compatibility of the FR-CN filler with the polymer by reacting hydroxyl groups on the surface of the cellulosic nanomaterial and a monomer (e.g., epichlorohydrin when the polymer is an epoxy-based polymer). | 2015-10-01 |
20150274849 | RESISTANT STARCH - A colourless resistant starch is produced by a process comprising (i) suspending starch in a C2-C4 alcohol, in particular ethanol, in the presence of 0.01-3.0% (w/w) of acid based on the starch; (ii) heating the suspended starch at a temperature of 70-160° C., in particular 78-120° C., and (c) isolating the resulting product. The resulting starch has a resistant fraction of at least 20%. | 2015-10-01 |
20150274850 | METHOD FOR PRODUCING A POLYVINYL ACETATE DISPERSION - A method for producing an aqueous adhesive dispersion, wherein a dispersion is produced from a sheet silicate having an SiO | 2015-10-01 |
20150274851 | PROCESS OF CONTROLLED RADICAL POLYMERIZATION OF BRANCHED POLYACRYLATES - The present invention relates to living radical polymerization processes, reaction products of such processes, and compositions containing such reaction products. More particularly, the invention relates to a living radical polymerization to produce branched polymers, in particular branched polyacrylates. | 2015-10-01 |
20150274852 | METALLOCENE CATALYST SUPPORTED BY HYBRID SUPPORTING MEANS, PROCESS FOR PRODUCING SAME, POLYMERIZATION PROCESS FOR PRODUCING AN ETHYLENE HOMOPOLYMER OR COPOLYMER WITH BROAD OR BIMODAL MOLAR MASS DISTRIBUTION, USE OF THE SUPPORTED METALLOCENE CATALYST AND ETHYLENE POLYMER WITH BROAD OR BIMODAL MOLAR MASS DISTRIBUTION - The present invention relates to a metallocene catalyst based on a transition metal of group 4 or 5 of the periodic table, supported on a hybrid catalytic support provided with aliphatic organic groups. | 2015-10-01 |
20150274853 | METHOD FOR PRODUCING COMPOUND HAVING COLORANT STRUCTURE AT MAIN CHAIN TERMINAL OF POLYMER, AND PIGMENT DISPERSANT, PIGMENT COMPOSITION, PIGMENT DISPERSION AND TONER CONTAINING COMPOUND OBTAINED BY THE PRODUCTION METHOD - To provide a method for producing a compound that enhances dispersibility of a pigment of respective colors in a water-insoluble solvent, as well as a pigment dispersant, and a pigment composition, a pigment dispersion and a toner having a good tinting power. A method for producing a compound, including the following: | 2015-10-01 |
20150274854 | SILICONE ACRYLAMIDE COPOLYMER - The present invention relates to a silicone acrylamide copolymer of high acrylamide monomer content which has transparency and low modulus, employing the following configuration. The copolymer is suitably used for various kinds of medical devices, particularly ophthalmic lenses such as a contact lens, an intraocular lens, an artificial cornea, and is especially suitable for a contact lens. A copolymer comprising (A) a multi-functional (meth)acrylamide monomer having at least one siloxane bond and at least two (meth)acrylamide groups within a molecule and (B) a mono-functional linear silicone (meth)acrylamide monomer. | 2015-10-01 |
20150274855 | SILICONE ACRYLAMIDE COPOLYMER - The present invention relates to copolymers obtained by polymerizing a mono-functional silicone (meth)acrylamide monomer with a non-silicon containing, multi-functional (meth)acrylamide monomer having at least two (meth)acrylamide groups in a molecule. The shortest chain length of an organic group connecting any two (meth)acrylamide groups in the multi-functional (meth)acrylamide monomer is:
| 2015-10-01 |
20150274856 | LOW DENSITY ETHYLENE-BASED POLYMERS WITH HIGH MELT STRENGTH - The invention provides a composition comprising a first ethylene-based polymer, formed by a high pressure, free-radical polymerization process, and comprising the following properties: a) a Mw(abs) versus 12 relationship: Mw(abs) | 2015-10-01 |
20150274857 | DISTANCE MEASURING METHOD AND DISTANCE MEASURING ELEMENT - The present invention provides a liquid organomagnesium precursor having formula {Mg(OR′)X}.a{MgX | 2015-10-01 |
20150274858 | Phenylene-Bridged Salalen Catalysts - A phenylene-bridged Salalen catalyst, a catalyst system comprising an activator and the phenylene-bridged Salalen catalyst, a process comprising contacting one or more olefins with the catalyst system, and polymers produced by the process are disclosed herein. | 2015-10-01 |
20150274859 | Mixed Compatible Ziegler-Natta / Chromium Catalysts for Improved Polymer Products - A catalyst system for polymerizing olefin-based polymers and interpolymers is disclosed. The catalyst system may include a supported chromium catalyst and a Ziegler-Natta catalyst comprising a bulking agent, Mg, and Ti. The Ziegler-Natta catalysts in catalyst systems disclosed herein run exceptionally well without addition of excessive amounts of co-catalyst, thus allowing for use of chromium based supported catalysts that would otherwise be overwhelmed by aluminum alkyl. Further, embodiments disclosed herein may be run without an internal electron donor, and the lack of an internal electron donor in the system also prevents poisoning of the chromium catalysts by the internal electron donor. By including or co-feeding a chromium based catalyst with these Ziegler-Natta catalysts, it has been found that the molecular architecture of the resulting polyolefins, such as polyethylenes, may provide for resins with excellent processing properties. | 2015-10-01 |
20150274860 | FLAME-RESISTANT FIBER BUNDLE, CARBON FIBER BUNDLE, AND PROCESSES FOR PRODUCING THESE - A process for producing a flame-resistant fiber bundle, the process comprising a step in which a flame-resistant fiber bundle (1) having a single-fiber density ρ | 2015-10-01 |
20150274861 | TACKIFIER COMPOUNDS AND METHODS OF USING THE SAME - The present invention relates to tackifier compounds and methods of using the same. In various embodiments, the present invention provides a tackifier compound including independently substituted or unsubstituted fused rings A and B each independently chosen from (C | 2015-10-01 |
20150274862 | METHOD FOR CONVERTING REACTIVE GROUPS OF SI-C-BOUND GROUPS OF SILANES WHILE SIMULTANEOUSLY INCREASING THE PHYSICAL DISTANCE BETWEEN SAID GROUPS - The present invention relates to a method for converting reactive groups of Si—C bound groups of silanes or siloxanes while simultaneously increasing the physical distance between said groups, the Si—C bound groups having the grouping-AW(Z)a,
| 2015-10-01 |
20150274863 | POLYBUTADIENE DERIVATIVE COMPOSITION - A composition containing a stabilizer that does not turn yellow upon curing and acts as a polymerization inhibitor during production and storage of a (meth)acrylic modified (hydrogenated) polybutadiene. The curable composition contains 0.1-99.9999% by weight of component (A), which is a (meth)acrylic modified (hydrogenated) polybutadiene, and 0.0001-10% by weight of component (B), which is a compound represented by formula (IV). | 2015-10-01 |
20150274864 | Injection Stretch Blow Molded Articles and Random Copolymers For Use Therein - A polymer composition adapted for use in injection stretch blow molding may include a metallocene random propylene-based copolymer in the absence of a clarifier. The metallocene random propylene-based copolymer may exhibit a melting point of from 105° C. to less than 175° C., a recrystallization temperature ranging from 85° C. to 100° C. as measured by DSC, a microtacticity ranging from 89% to 99%, a molecular weight (Mw) ranging from 170,000 to 210,000, and a melt flow rate of from about 1 dg/min. to about 40 dg/min. A method of forming an injection stretch blow molded (ISBM) article may include providing the metallocene random propylene-based copolymer, injection molding the metallocene random propylene-based copolymer in the absence of a clarifier into a preform, and stretch-blowing the preform into an article. | 2015-10-01 |
20150274865 | TERPENE/ISOOLEFIN COPOLYMERS HAVING SUBSTANTIALLY HETEROGENEOUS COMPOSITIONAL DISTRIBUTION AND DISPLAYING THERMOPLASTIC ELASTOMERIC PROPERTIES - Copolymers having a substantially heterogeneous composition distribution and strong UV absorption are the direct reaction product of an isoolefin and at least one terpene having the molecular formulae of (C | 2015-10-01 |
20150274866 | POLYETHYLENE COMPOSITION HAVING HIGH SWELL RATIO - Polyethylene composition with improved swell ratio and mechanical properties, particularly suited for preparing blow-moulded articles, said composition having the following features: | 2015-10-01 |
20150274867 | ETHYLENE/ALPHA-OLEFIN/POLYENE BASED COMPOSITIONS - The invention provides a composition comprising a first composition that comprises at least one ethylene/alpha-olefin/nonconjugated polyene interpolymer; and wherein the first composition has a Mooney Viscosity (ML1+4, 125 C) greater than, or equal to, 10, and wherein the first composition has a “13C NMR % Peak Area,” which is the {[(13C NMR peak area from 21.3 ppm to 21.8 ppm) divided by the (total integral area from 19.5 ppm to 22.0 ppm)]×100}, that is greater than 3.5 percent, as determined by 13C NMR. | 2015-10-01 |
20150274868 | HIGHLY FLUORINATED POLYMERS - A method of making a highly fluorinated polymers and resulting aqueous mixtures. The method comprising polymerizing one or more perfluorinated monomers in an aqueous emulsion polymerization in the presence of a polymerizable fluorinated emulsifier to form a perfluorinated polymer. The polymerizable fluorinated emulsifier has the formula X | 2015-10-01 |
20150274869 | NANOHYBRID POLYMERS FOR OPHTHALMIC APPLICATIONS - The present invention relates to novel materials particularly useful for ophthalmic applications and methods for making and using the same. More particularly, the present invention relates to relatively soft, optically transparent, foldable, high refractive index materials particularly suited for use in the production of intraocular lenses, contact lenses, and other ocular implants and to methods for manufacturing and using the same. | 2015-10-01 |
20150274870 | PERFLUOROALKYLENE ETHER-CONTAINING COMPOUND AND SURFACE PROTECTIVE FILM - Provided is a perfluoroalkylene ether-containing compound represented by the following general formula (1): | 2015-10-01 |
20150274871 | COMPOSITION - A composition suitable for manufacturing components and devices (e.g., optical or electronic components, films, and devices) is disclosed. Such compositions may comprise a first compound having a first polymerizable group, a second polymerizable group, and a third polymerizable group. The first compound preferably has no aromatic group, and the second compound is preferably able to generate a radical by cleavage of a bond of the second compound. The first polymerizable group, the second polymerizable group and the third polymerizable group may be identical substituents. Further, the first polymerizable group may be connected to a first chain connected to a first atom; the second polymerizable group may be connected to a second chain connected to the first atom; and the third polymerizable group may be connected to a third chain connected to the first atom. | 2015-10-01 |
20150274872 | POLYMERIZABLE COMPOUND, POLYMERIZABLE COMPOSITION, POLYMER, AND OPTICAL ANISOTROPIC BODY - The present invention pertains to: a polymerizable compound represented by a formula (I); a polymerizable composition comprising the polymerizable compound and an initiator; a polymer obtained by polymerizing the polymerizable compound or the polymerizable composition; and an optically anisotropic article comprising the polymer. The present invention provides a polymerizable compound, a polymerizable composition, and a polymer that have a practical low melting point, exhibit excellent solubility in a general-purpose solvent, can be produced at low cost, and can produce an optical film that achieves uniform conversion of polarized light over a wide wavelength band, and also provide an optically anisotropic article. | 2015-10-01 |
20150274873 | METHOD FOR DEGRADING (CO)POLYMERS IN AN EXTRUDER AND EXTRUDER FOR PERFORMING THE METHOD - The invention relates to a method for degrading (co)polymers in an extruder and an extruder suitable for performing said method. | 2015-10-01 |
20150274874 | ELASTIC TERPOLYMER INCLUDING DIENE GROUP AND PREPARATION METHOD THEREOF - The present invention relates to an elastic terpolymer which can satisfy excellent processability and elasticity (flexibility) at the same time, and a preparation method thereof. The elastic terpolymer is a copolymer of 40 to 70 weight % of ethylene, 15 to 55 weight % of a C | 2015-10-01 |
20150274875 | PROCESS FOR PREPARING LOW SULFUR DISPERSANT POLYMERS - The present invention relates to a process for preparing grafted polyalkyl(meth)acrylates (PAMAs) containing dispersant repeating units in the polymer backbone as well as in the grafted layer, which polymers are characterized by a low sulfur content, the products available by this process and their use as an additive to fuels, especially to middle distillates and blends thereof. The present invention further relates to a composition comprising the grafted polyalkyl(meth)acrylates prepared by the process according to the present invention and the use of said composition as an additive component to fuels, especially to middle distillates and blends thereof, and for improving the cold flow properties of fuel oil and fuel oil compositions, especially to middle distillate fuels and blends thereof. | 2015-10-01 |
20150274876 | HIGH STRENGTH POLYISOBUTYLENE POLYURETHANES - An elastomeric polymer, comprising (1) a hard segment in the amount of 10% to 60% by weight of the elastomeric polymer, wherein the hard segment includes a urethane, urea, or urethaneurea; and (2) a soft segment in the amount of 40% to 90% by weight of the elastomeric polymer, wherein the soft segment includes a polyisobutylene macrodiol and/or diamine. Additionally disclosed is a method of forming a polyisobutylene-based thermoplastic urethane, comprising the steps of (a) reacting a polyisobutylene macrodiol and/or diamine with a diisocyanate to form a first reaction mixture; (b) combining a metal catalyst and a chain extender with the first reaction mixture to create a second reaction mixture, a molar ratio of the metal catalyst to the diisocyanate being greater than 0.0:1 and less than or equal to 0.4:1; and (c) reacting the second reaction mixture for a period of time sufficient to form the polyisobutylene-based thermoplastic urethane. | 2015-10-01 |
20150274877 | CURABLE COMPOSITIONS BASED ON POLYURETIDIONES, POLYTHIOLS AND PHOTOACTIVABLE BASES AND GENERATION OF ISOCYANATES FROM URETIDIONES - Curable compositions based on polyuretidiones, polythiols and photoactivable bases are disclosed. Also a process for generating isocyanate groups by exposing uretidiones to radiation in the range of 100-315 nm is disclosed. The process can be used in a dual curing system for curing compositions that comprise groups that under go photoinduced polymerizations and active hydrogen groups that react with the generated isocyanates. | 2015-10-01 |
20150274878 | SULPHUR-COMPRISING POLYAROMATIC POLYAMINE THAT CAN BE USED IN THE SYNTHESIS OF POLYUREA - A sulphur-comprising polyaromatic polyamine compound can be used as a monomer or prepolymer, when n is different from zero, in the synthesis of polyurea. The compound corresponds to the formula (I): | 2015-10-01 |
20150274879 | TONER - A toner has toner particles containing a binder resin that comprises a block polymer as a main component, obtained by chemically bonding a crystalline polyester resin with an amorphous polyurethane resin, wherein the binder resin has a specific content of a crystalline polyester resin component, and has a concentration of ester bonds derived from the crystalline polyester resin component of not more than 5.2 mmol/g, and The maximum value E | 2015-10-01 |
20150274880 | POLYISOCYANATES FROM FUSED BICYCLIC POLYOLS AND POLYURETHANES THEREFROM - The present invention is directed to polyisocyanates and polyurethanes derived therefrom. In various embodiments, the present invention provides polyisocyanates, methods of making the polyisocyanates from fused bicyclic alcohols, polyurethanes, and methods of making the polyurethanes from the polyisocyanates. | 2015-10-01 |
20150274881 | AQUEOUS DISPERSIONS OF A MULTIFUNCTIONAL PRIMARY AMINE, PROCESS FOR ITS PREPARATION, AND USE THEROF - The invention relates to a curing agent for epoxy resins which is an aqueous dispersion of a multifunctional amine AC having more than one primary amino group per molecule, and at least one moiety per molecule derived from the reaction of a compound C containing at least one reactive group which is preferably an epoxide group, with a molecule having at least one blocked primary amino group and at least one group which is reactive towards the at least one reactive group of compound C, which is selected from the group consisting of secondary amino groups >NH, of hydroxyl groups —OH, of mercaptan groups —SH, of amide groups —CO—NHR, where R can be hydrogen or an alkyl group having from one to twelve carbon atoms, of hydroxyester groups, and of acid groups, particularly of carboxyl groups —COOH, sulphonic acid groups —SO | 2015-10-01 |
20150274882 | METHOD FOR PREPARING POLYALKYLENECARBONATE - This disclosure relates to a method for preparing polyalkylenecarbonate. More specifically, in the method for preparing polyalkylenecarbonate, by using a solution polymerization with a specific heterogeneous catalyst and a solvent in the polymerization process of an epoxide compound and carbon dioxide, the products of side-reaction are reduced, removal of metal residues and by-products from the products is facilitated, danger due to overheating of the reactants is minimized, and heat removal and process stability are improved, and thus, high molecular weight copolymer may be easily provided, and mass production and scale-up are easy. | 2015-10-01 |
20150274883 | POLY(DIHYDROFERULIC ACID) A BIORENEWABLE POLYETHYLENE TEREPHTHALATE MIMIC DERIVED FROM LIGNIN AND ACETIC ACID AND COPOLYMERS THEREOF - An embodiment of the invention is directed to a biorenewable thermoplastic, poly(dihydroferulic acid) (PHFA), which is an effective polyethylene terephthalate (PET) mimic. In another embodiment of the invention, a biorenewable thermoplastic copolymer, poly(dihydroferulic acid-co-ferulic acid) is an effective polystyrene mimic. The PHFA and the copolymer can be prepared by the homocondensation of acetyldihydroferulic acid or the copolymerization of acetyldihydroferulic acid with acetylferulic acid, which are monomers that can be synthesized from starting materials isolated from lignin, rice bran, or other biorenewable sources. | 2015-10-01 |
20150274884 | Fluorinated Soluble Aromatic Polyester - An aromatic polyester that contains a combination of biphenyl repeating units, fluoro-substituted aromatic repeating units, and aromatic ester repeating units is provided. Through selective control over the nature and concentration of the biphenyl and fluoro-substituted aromatic repeating units, the resulting polymer can have a low dielectric constant and still remain generally soluble or dispersible in a solvent system. | 2015-10-01 |
20150274885 | PHOTORESPONSIVE COUMARIN BASED POLYMERS: SYNTHESIS AND APPLICATIONS - A photoactive coumarin monomer includes a substituted coumarin molecule that has at least two functional groups may be used to produce a polymer with a coumarin unit or a coumarin derivative unit as part of the polymer backbone. The polymer with a coumarin unit or a coumarin derivative unit as part of the polymer backbone may be photoresponsive and/or bioabsorbable. Photoresponsive polymers with a coumarin unit or a coumarin derivative unit as part of the polymer backbone may crosslink when irradiated at a wavelength of about 320 nm to about 420 nm. The crosslink may be separated when the polymers are irradiated at a wavelength of about 230 nm to about 300. The polymers may also photocleave when irradiated with light at a wavelength of about 230 nm to about 300. | 2015-10-01 |